8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 2, 2026·SEC
Material company update
Feb 3, 2026·SEC
Aytu BioPharma, Inc.(AYTU)Earnings, Financials & Key Ratios
AYTU•NASDAQ
Price updated Jun 19, 2026
AboutAytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.Show more
- Revenue$66M+1.8%
- EBITDA-$2M-147.7%
- Net Income-$14M+14.4%
- EPS (Diluted)-2.16+24.5%
- Gross Margin69.04%-8.3%
- EBITDA Margin-3.69%-146.9%
- Operating Margin-11.79%-383.1%
- Net Margin-20.43%+15.9%
- ROE-58.1%-23.0%
AYTU Key Insights
Aytu BioPharma, Inc. (AYTU) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 19.2%
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 13.4% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AYTU posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AYTU Price & Volume
Aytu BioPharma, Inc. (AYTU) stock price & volume — 10-year historical chart
Loading chart...
AYTU Growth Metrics
Aytu BioPharma, Inc. (AYTU) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years73.94%
5 Years19.16%
3 Years-11.78%
TTM-18.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2177.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-535.74%
Return on Capital
10 Years-70.95%
5 Years-35.52%
3 Years-13.29%
Last Year-13.3%
AYTU Recent Earnings
Aytu BioPharma, Inc. (AYTU) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.53-19.5%
$0.44
Rev
$12M+3.0%
$12M
Q1 2026
Feb 3, 2026Metric
Actual
Est
EPS
$1.05-303.8%
$0.26
Rev
$15M+24.9%
$12M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.08-33.3%
$0.06
Rev
$14M+10.2%
$13M
Q4 2025
Sep 23, 2025Metric
Actual
Est
EPS
$0.26-1200.0%
$0.02
Rev
$15M-15.5%
$18M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.53vs $0.44-19.5% | $12Mvs $12M+3.0% |
| Q1 2026 | Feb 3, 2026 | $1.05vs $0.26-303.8% | $15Mvs $12M+24.9% |
| Q4 2025 | Nov 13, 2025 | $0.08vs $0.06-33.3% | $14Mvs $13M+10.2% |
| Q4 2025 | Sep 23, 2025 | $0.26vs $0.02-1200.0% | $15Mvs $18M-15.5% |
Based on last 12 quarters of dataView full earnings history →
AYTU Peer Comparison
Aytu BioPharma, Inc. (AYTU) competitors in Specialty pharma brand consolidators — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 ASRT | 151.86M | 23.50 | -4.96 | -5% | -34.94% | -38.72% | 0.42 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 COLL | 1.09B | 33.54 | 19.39 | 23.62% | 9.41% | 26.74% | 3.12 | |
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 TEVA | 36.66B | 31.48 | 26.23 | 4.31% | 9.02% | 20.69% | 2.20 |
Compare AYTU vs Peers
Aytu BioPharma, Inc. (AYTU) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AYTU Income Statement
Aytu BioPharma, Inc. (AYTU) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 3.22M | 3.66M | 7.32M | 27.63M | 65.63M | 96.67M | 107.4M | 65.18M | 66.38M | 56.6M |
Revenue Growth % | 25.72% | 13.61% | 100.01% | 277.47% | 137.52% | 47.29% | 11.1% | -39.31% | 1.84% | -18.24% |
Cost of Goods Sold | 1.42M | 2.05M | 2.2M | 8.28M | 36.43M | 46.39M | 40.77M | 16.13M | 20.55M | 21.22M |
COGS % of Revenue | 44% | 56.03% | 30.08% | 29.97% | 55.51% | 47.98% | 37.96% | 24.74% | 30.96% | - |
Gross Profit | 1.8M▲ 0% | 1.61M▼ 10.8% | 5.12M▲ 218.0% | 19.35M▲ 278.1% | 29.2M▲ 50.9% | 50.28M▲ 72.2% | 66.63M▲ 32.5% | 49.05M▼ 26.4% | 45.83M▼ 6.6% | 35.38M▲ 0% |
Gross Margin % | 56% | 43.97% | 69.92% | 70.03% | 44.49% | 52.02% | 62.04% | 75.26% | 69.04% | 62.5% |
Gross Profit Growth % | 12.39% | -10.8% | 218.02% | 278.07% | 50.9% | 72.2% | 32.51% | -26.38% | -6.57% | - |
Operating Expenses | 20.66M | 19.45M | 21.96M | 40.48M | 88.07M | 160.19M | 83.7M | 50.65M | 53.66M | 50.54M |
OpEx % of Revenue | 641.43% | 531.51% | 300.05% | 146.5% | 134.19% | 165.71% | 77.93% | 77.7% | 80.83% | - |
Selling, General & Admin | 17.61M | 17.73M | 19.24M | 31.06M | 55.81M | 69.88M | 70.08M | 42.04M | 38.28M | 40.69M |
SG&A % of Revenue | 546.55% | 484.48% | 262.82% | 112.41% | 85.03% | 72.29% | 65.25% | 64.49% | 57.67% | - |
Research & Development | 1.35M | 167.59K | 589.07K | 1.72M | 5.62M | 12.66M | 4.09M | 2.77M | 1.33M | 216K |
R&D % of Revenue | 41.84% | 4.58% | 8.05% | 6.23% | 8.57% | 13.1% | 3.81% | 4.25% | 2% | - |
Other Operating Expenses | 1.71M | 6.28M | 2.14M | 7.7M | 26.64M | 77.65M | 9.52M | 5.84M | 14.05M | 1.44M |
Operating Income | -20.13M▲ 0% | -19.7M▲ 2.1% | -16.85M▲ 14.5% | -21.13M▼ 25.4% | -58.87M▼ 178.6% | -109.91M▼ 86.7% | -17.07M▲ 84.5% | -1.59M▲ 90.7% | -7.83M▼ 392.0% | -15.16M▲ 0% |
Operating Margin % | -624.7% | -538.26% | -230.13% | -76.47% | -89.7% | -113.69% | -15.89% | -2.44% | -11.79% | -26.79% |
Operating Income Growth % | 7.28% | 2.11% | 14.49% | -25.43% | -178.6% | -86.69% | 84.47% | 90.68% | -391.95% | - |
EBITDA | -18.28M | -17.85M | -14.61M | -15.42M | -49.67M | -99.76M | -8.25M | 5.13M | -2.45M | -11.06M |
EBITDA Margin % | -567.5% | -487.77% | -199.59% | -55.79% | -75.68% | -103.2% | -7.68% | 7.88% | -3.69% | -19.54% |
EBITDA Growth % | 12.23% | 2.35% | 18.16% | -5.52% | -222.17% | -100.85% | 91.73% | 162.23% | -147.72% | -650.97% |
D&A (Non-Cash Add-back) | 1.84M | 1.85M | 2.24M | 5.71M | 9.2M | 10.15M | 8.81M | 6.72M | 5.38M | 4.1M |
EBIT | -19.97M | -17.84M | -16.85M | -17.92M | -38.24M | -38.1M | -12.09M | -5.32M | -10.04M | -30.32M |
Net Interest Income | -2.53M | -749.42K | 0 | 0 | 0 | -147.48M | -4.96M | -4.79M | -3.7M | -2.24M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 14K | 0 | 0 | 0 | 0 |
Interest Expense | 2.53M | 749.42K | 0 | 0 | 0 | 147.5M | 4.96M | 4.79M | 3.7M | 2.24M |
Other Income/Expense | -2.38M | 9.51M | -10.29M | 7.51M | 840K | 1.02M | 14K | -8.79M | -5.92M | -18.51M |
Pretax Income | -22.51M▲ 0% | -10.19M▲ 54.7% | -27.13M▼ 166.3% | -13.62M▲ 49.8% | -58.03M▼ 326.0% | -108.89M▼ 87.6% | -17.05M▲ 84.3% | -10.38M▲ 39.1% | -13.74M▼ 32.4% | -33.67M▲ 0% |
Pretax Margin % | -698.67% | -278.36% | -370.64% | -49.29% | -88.42% | -112.64% | -15.88% | -15.92% | -20.71% | -59.49% |
Income Tax | 0 | 0 | 20.04M | 0 | 259K | -110K | 0 | 2.14M | 437K | 447K |
Effective Tax Rate % | 0% | 0% | -73.84% | 0% | -0.45% | 0.1% | 0% | -20.64% | -3.18% | -1.33% |
Net Income | -22.51M▲ 0% | -10.19M▲ 54.7% | -47.17M▼ 363.0% | -13.62M▲ 71.1% | -58.29M▼ 327.9% | -108.78M▼ 86.6% | -17.05M▲ 84.3% | -15.84M▲ 7.1% | -13.56M▲ 14.4% | -34.05M▲ 0% |
Net Margin % | -698.67% | -278.36% | -644.33% | -49.29% | -88.81% | -112.53% | -15.88% | -24.31% | -20.43% | -60.17% |
Net Income Growth % | 20.13% | 54.74% | -362.97% | 71.12% | -327.93% | -86.62% | 84.33% | 7.08% | 14.4% | -2177.79% |
Net Income (Continuing) | -22.51M | -10.19M | -27.13M | -13.62M | -58.29M | -108.78M | -17.05M | -12.52M | -14.18M | -34.12M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.32M | 620K | 62K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -193194.38▲ 0% | -3061.23▲ 98.4% | -1210.28▲ 60.5% | -60.20▲ 95.0% | -69.60▼ 15.6% | -74.01▼ 6.3% | -5.11▲ 93.1% | -2.86▲ 44.0% | -2.16▲ 24.5% | -3.24▲ 0% |
EPS Growth % | 85.08% | 98.42% | 60.46% | 95.03% | -15.61% | -6.34% | 93.1% | 44.03% | 24.48% | -535.74% |
EPS (Basic) | -193194.38 | -3061.23 | -1210.28 | -60.20 | -69.60 | -74.01 | -5.11 | -2.86 | -2.16 | - |
Diluted Shares Outstanding | 117 | 3.33K | 38.97K | 230K | 840K | 1.47M | 3.34M | 5.54M | 6.28M | 10.51M |
Basic Shares Outstanding | 117 | 3.33K | 38.97K | 230K | 840K | 1.47M | 3.34M | 5.54M | 6.28M | 10.51M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AYTU Balance Sheet
Aytu BioPharma, Inc. (AYTU) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.03M | 9.47M | 15.43M | 75.42M | 105.23M | 59.93M | 72.83M | 61.89M | 79.18M | 67.33M |
Cash & Short-Term Investments | 802.33K | 7.01M | 11.04M | 48.08M | 49.65M | 19.36M | 22.98M | 20.01M | 30.95M | 26.71M |
Cash Only | 802.33K | 7.01M | 11.04M | 48.08M | 49.65M | 19.36M | 22.98M | 20.01M | 30.95M | 26.71M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 528.04K | 578.78K | 1.74M | 5.63M | 28.18M | 21.71M | 28.94M | 23.53M | 31.16M | 24.49M |
Days Sales Outstanding | 59.83 | 57.72 | 86.8 | 74.41 | 156.7 | 81.98 | 98.34 | 131.74 | 171.31 | 193.13 |
Inventory | 1.31M | 1.34M | 1.44M | 10M | 16.34M | 10.85M | 11.99M | 12.14M | 11.43M | 7.46M |
Days Inventory Outstanding | 337.93 | 238.34 | 238.7 | 440.72 | 163.69 | 85.37 | 107.4 | 274.75 | 203.08 | 161.88 |
Other Current Assets | 75.21K | 100K | 250K | 5.99M | 1.29M | 633K | 868K | 1.12M | 0 | 8.66M |
Total Non-Current Assets | 11.97M | 11.59M | 19.29M | 77.87M | 160.43M | 77.69M | 65.01M | 56.97M | 45M | 44.36M |
Property, Plant & Equipment | 647.25K | 219K | 203.73K | 893K | 8.7M | 6.3M | 3.87M | 1.52M | 1.59M | 1.32M |
Fixed Asset Turnover | 4.98x | 16.71x | 35.93x | 30.94x | 7.54x | 15.35x | 27.76x | 42.83x | 41.67x | 38.61x |
Goodwill | 238.43K | 0 | 0 | 28.09M | 65.8M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 11.08M | 11.37M | 19.08M | 48.85M | 85.46M | 70.63M | 58.97M | 52.45M | 42.2M | 42.49M |
Long-Term Investments | 0 | 0 | 0 | 0 | -10.91M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 2.89K | 4.72K | 2.2K | 33K | 465K | 766K | 792K | 2.23M | 1.2M | 556K |
Total Assets | 15M▲ 0% | 21.06M▲ 40.4% | 34.72M▲ 64.9% | 153.29M▲ 341.5% | 265.67M▲ 73.3% | 137.62M▼ 48.2% | 137.84M▲ 0.2% | 118.86M▼ 13.8% | 124.18M▲ 4.5% | 111.69M▲ 0% |
Asset Turnover | 0.21x | 0.17x | 0.21x | 0.18x | 0.25x | 0.70x | 0.78x | 0.55x | 0.53x | 0.47x |
Asset Growth % | -38.39% | 40.41% | 64.87% | 341.49% | 73.31% | -48.2% | 0.16% | -13.77% | 4.48% | 7.27% |
Total Current Liabilities | 3.61M | 3.39M | 5.37M | 28.76M | 109.44M | 64.44M | 69.02M | 62.23M | 63.06M | 59.97M |
Accounts Payable | 2.22M | 2.12M | 2.13M | 11.64M | 19.25M | 10.99M | 13.48M | 10.31M | 10.6M | 13.21M |
Days Payables Outstanding | 571.8 | 377.3 | 353.64 | 513.05 | 192.91 | 86.45 | 120.67 | 233.41 | 188.28 | 216.77 |
Short-Term Debt | 0 | 0 | 0 | 982K | 24.6M | 3.81M | 8.74M | 4.96M | 10.92M | 12.47M |
Deferred Revenue (Current) | 0 | 0 | 0 | 339.34K | 57.23M | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.05M | 734.43K | 2.23M | 8M | 1.47M | 23.84M | 41.12M | 42.35M | 26.14M | 34.29M |
Current Ratio | 0.84x | 2.79x | 2.87x | 2.62x | 0.96x | 0.93x | 1.06x | 0.99x | 1.26x | 1.12x |
Quick Ratio | 0.48x | 2.40x | 2.60x | 2.27x | 0.81x | 0.76x | 0.88x | 0.80x | 1.07x | 1.00x |
Cash Conversion Cycle | -174.05 | -81.25 | -28.15 | 2.08 | 127.48 | 80.89 | 85.07 | 173.08 | 186.1 | 138.24 |
Total Non-Current Liabilities | 7.39M | 4.24M | 22.26M | 29.52M | 18.66M | 28.87M | 29.47M | 28.91M | 42.15M | 16.57M |
Long-Term Debt | 0 | 0 | 0 | 0 | 2.8M | 14.2M | 20.86M | 10.88M | 10.89M | 9.55M |
Capital Lease Obligations | 0 | 0 | 0 | 725K | 2.62M | 84K | 832K | 577K | 985K | 2.88M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 11.15M | 0 | 1.38M | 762K | 0 | 0 |
Other Non-Current Liabilities | 7.39M | 4.24M | 22.26M | 28.79M | 13.23M | 14.59M | 6.4M | 16.7M | 30.27M | 6.11M |
Total Liabilities | 11M | 7.64M | 27.63M | 58.28M | 128.1M | 93.31M | 98.48M | 91.14M | 105.21M | 76.55M |
Total Debt | 0 | 0 | 0 | 2.01M | 30.97M | 18.19M | 30.43M | 16.42M | 22.94M | 22.94M |
Net Debt | -802.33K | -7.01M | -11.04M | -46.08M | -18.68M | -1.17M | 7.44M | -3.59M | -8.02M | -3.78M |
Debt / Equity | - | - | - | 0.02x | 0.23x | 0.41x | 0.77x | 0.59x | 1.21x | 0.65x |
Debt / EBITDA | - | - | - | - | - | - | - | 3.20x | - | -2.07x |
Net Debt / EBITDA | - | - | - | - | - | - | - | -0.70x | - | 0.34x |
Interest Coverage | -7.88x | -23.81x | - | - | - | -0.26x | -2.44x | -1.11x | -2.71x | -13.52x |
Total Equity | 4M▲ 0% | 13.42M▲ 235.6% | 7.09M▼ 47.2% | 95.02M▲ 1240.5% | 137.57M▲ 44.8% | 44.31M▼ 67.8% | 39.36M▼ 11.2% | 27.72M▼ 29.6% | 18.97M▼ 31.6% | 35.14M▲ 0% |
Equity Growth % | -60.34% | 235.63% | -47.2% | 1240.54% | 44.79% | -67.79% | -11.17% | -29.58% | -31.57% | -107.02% |
Book Value per Share | 34331.42 | 4033.78 | 181.87 | 413.11 | 163.77 | 30.14 | 11.78 | 5.00 | 3.02 | 3.34 |
Total Shareholders' Equity | 4M | 13.42M | 7.09M | 95.02M | 137.57M | 44.31M | 39.36M | 27.72M | 18.97M | 35.14M |
Common Stock | 82 | 179 | 1.75K | 1K | 3K | 0 | 1K | 1K | 1K | 1K |
Retained Earnings | -69.07M | -79.26M | -106.39M | -120.01M | -178.3M | -287.08M | -304.13M | -319.97M | -333.54M | -347.77M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -246K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AYTU Cash Flow Statement
Aytu BioPharma, Inc. (AYTU) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -13.83M | -15.94M | -13.83M | -28.37M | -25.96M | -28.82M | -5.13M | -1.39M | -1.94M | 1.68M |
Operating CF Margin % | -429.28% | -435.53% | -188.94% | -102.68% | -39.56% | -29.82% | -4.78% | -2.13% | -2.92% | - |
Operating CF Growth % | -29.77% | -15.26% | 13.23% | -105.14% | 8.49% | -11.01% | 82.21% | 72.94% | -39.55% | 565.5% |
Net Income | -22.51M | -10.19M | -27.13M | -13.62M | -58.29M | -108.78M | -17.05M | -15.84M | -13.56M | -34.05M |
Depreciation & Amortization | 4.36M | 2.59M | 2.73M | 6.25M | 9.2M | 10.15M | 8.81M | 6.72M | 5.38M | 4.1M |
Stock-Based Compensation | 2.5M | 348.51K | 1.02M | 1.08M | 3.57M | 5.25M | 6.05M | 2.37M | 576K | 397K |
Deferred Taxes | 1.62M | -1.94M | -80.78K | 573.53K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 1.23M | -6.03M | 9.84M | -10.04M | 17.87M | 75.42M | 2.86M | 10.02M | 11.4M | 27.51M |
Working Capital Changes | -1.04M | -718.81K | -210.2K | -12.61M | 1.68M | -10.86M | -5.8M | -4.66M | -5.73M | 3.79M |
Change in Receivables | -355.03K | -50.74K | -1.16M | -3.56M | 1.54M | 6.53M | -7.15M | 5.2M | -7.63M | 11.34M |
Change in Inventory | 195.43K | -26.75K | -101.1K | -6.95M | 2.79M | 1.3M | -3.61M | -4.82M | 382K | 1.69M |
Change in Payables | 493.22K | -109.71K | 134.78K | -1.38M | -3.25M | -7.68M | 2.38M | -2.08M | 287K | -1.83M |
Cash from Investing | -3.53M | -484.29K | -1.06M | -5.66M | -2.78M | -3.25M | -117K | -329K | -2.56M | -3.03M |
Capital Expenditures | -111.61K | -74.71K | -59.85K | 0 | 0 | 0 | 0 | -329K | -228K | -3.03M |
CapEx % of Revenue | 3.46% | 2.04% | 0.82% | - | - | - | - | 0.5% | 0.34% | 5.36% |
Acquisitions | -4.04M | -7.38K | -505.02K | 188.23K | -481K | -3.18M | -5K | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 613.31K | -402.2K | -497.11K | -5.84M | -2.3M | -70K | -112K | 0 | -2.33M | 0 |
Cash from Financing | 10.19M | 22.66M | 19.08M | 71.07M | 30.31M | 1.53M | 8.87M | -1.26M | 15.44M | 9.9M |
Debt Issued (Net) | 0 | 0 | 5M | -16.25M | -3.74M | -5.22M | -2.35M | -1.89M | 6.67M | -4.94M |
Equity Issued (Net) | 9.34M | 24.74M | 0 | 131.46M | 40.15M | 11.69M | 15.57M | 3.47M | 14.84M | 14.84M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 845.19K | -2.08M | 14.08M | -44.14M | -6.09M | -4.94M | -4.36M | -2.84M | -6.07M | 0 |
Net Change in Cash | -7.18M▲ 0% | 6.23M▲ 186.9% | 4.18M▼ 32.9% | 37.04M▲ 785.7% | 1.57M▼ 95.8% | -30.54M▼ 2047.8% | 3.63M▲ 111.9% | -2.98M▼ 182.2% | 10.95M▲ 467.4% | 8.54M▲ 0% |
Free Cash Flow | -13.94M▲ 0% | -16.02M▼ 14.9% | -13.89M▲ 13.3% | -28.37M▼ 104.3% | -25.96M▲ 8.5% | -28.82M▼ 11.0% | -5.13M▲ 82.2% | -1.72M▲ 66.5% | -5.17M▼ 200.8% | 1.64M▲ 0% |
FCF Margin % | -432.74% | -437.57% | -189.76% | -102.68% | -39.56% | -29.82% | -4.78% | -2.63% | -7.78% | 2.9% |
FCF Growth % | -7.98% | -14.88% | 13.26% | -104.26% | 8.49% | -11.01% | 82.21% | 66.52% | -200.82% | 127.09% |
FCF per Share | -119661.30 | -4812.17 | -356.44 | -123.36 | -30.91 | -19.61 | -1.54 | -0.31 | -0.82 | 0.16 |
FCF Conversion (FCF/Net Income) | 0.61x | 1.56x | 0.29x | 2.08x | 0.45x | 0.26x | 0.30x | 0.09x | 0.14x | -0.05x |
Interest Paid | 0 | 0 | 0 | 0 | 1.25M | 3.15M | 3.81M | 4.04M | 2.82M | 466K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.61M | 1.42M | 140K |
AYTU Key Ratios
Aytu BioPharma, Inc. (AYTU) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -319.61% | -116.94% | -459.89% | -26.68% | -50.12% | -119.62% | -40.76% | -47.24% | -58.1% | -148.91% |
Return on Invested Capital (ROIC) | -577.37% | -307.51% | -1029.09% | -70.46% | -52.62% | -101.75% | -28.46% | -3.36% | -33.47% | -67.6% |
Gross Margin | 56% | 43.97% | 69.92% | 70.03% | 44.49% | 52.02% | 62.04% | 75.26% | 69.04% | 62.5% |
Net Margin | -698.67% | -278.36% | -644.33% | -49.29% | -88.81% | -112.53% | -15.88% | -24.31% | -20.43% | -60.17% |
Debt / Equity | - | - | - | 0.02x | 0.23x | 0.41x | 0.77x | 0.59x | 1.21x | 0.65x |
Interest Coverage | -7.88x | -23.81x | - | - | - | -0.26x | -2.44x | -1.11x | -2.71x | -13.52x |
FCF Conversion | 0.61x | 1.56x | 0.29x | 2.08x | 0.45x | 0.26x | 0.30x | 0.09x | 0.14x | -0.05x |
Revenue Growth | 25.72% | 13.61% | 100.01% | 277.47% | 137.52% | 47.29% | 11.1% | -39.31% | 1.84% | -18.24% |
Related:AYTU Dividend History·AYTU Revenue History·AYTU Price History·AYTU P/E History·AYTU Financial Ratios·AYTU Institutional Holders
AYTU SEC Filings & Documents
Aytu BioPharma, Inc. (AYTU) SEC filings — annual & quarterly reports (10-K, 10-Q)
AYTU Frequently Asked Questions
Aytu BioPharma, Inc. (AYTU) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aytu BioPharma, Inc. (AYTU) reported $56.6M in revenue for fiscal year 2025.
Aytu BioPharma, Inc. (AYTU) grew revenue by 1.8% over the past year. Growth has been modest.
Aytu BioPharma, Inc. (AYTU) reported a net loss of $34.1M for fiscal year 2025.
Dividend & Returns
Aytu BioPharma, Inc. (AYTU) has a return on equity (ROE) of -58.1%. Negative ROE indicates the company is unprofitable.
Aytu BioPharma, Inc. (AYTU) generated $1.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.